Application of Convalescent Plasma in the Treatment of SARS CoV-2 Disease (COVID-19) With Evaluation of Therapy Effectiveness

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

396 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-12-22

Study Completion Date

2022-01-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Multi-centre, 18-months, Single-group Study of Application of Convalescent Plasma in the Treatment of SARS CoV-2 Disease (COVID-19) With Metabolomic and Laboratory Evaluation of Plasma Therapy Effectiveness.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Convalescent Plasma to Limit Coronavirus Associated Complications

NCT04325672

Coronavirus

WITHDRAWN PHASE2

CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients

NCT04364737

COVID-19 Coronavirus Coronavirus Infection

COMPLETED PHASE2

Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19

NCT04393727

COVID SARS-CoV 2

TERMINATED PHASE2

Convalescent Plasma for Early Treatment of COVID-19

NCT04390503

SARS-CoV 2 COVID-19

TERMINATED PHASE2

Convalescent Plasma for the Treatment of COVID-19

NCT04389710

COVID-19

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The trial is designed as multi-centre, non-randomized, single-group with a primary endpoint of death of convalescent plasma recipient in twenty eight days. We are planning to recruit 300 donor patients who recovered from COVID-19 and who offer to take part in an experiment based on the informed consent form. The recovery criteria involve body temperature normalization for more than 3 days, resolution of respiratory tract symptoms, and two consecutively negative results of SARS-CoV-2 RT-PCR assay test. The donor's blood will be collected after four weeks post-onset of illness. 600 ml ABO-compatible plasma sample will be harvested during apheresis from each donor and each sample will be divided and stored as 200 mL aliquots. The plasma recipients are adult patients diagnosed with COVID-19 according to the WHO Interim Guidance with confirmation by real-time RT-PCR assay The inclusion criteria to receive plasma assume to meet at least one of following : respiratory distress with tachypnoe ≥30 breaths per minute, oxygen level less than 94% in resting-state, partial pressure of oxygen (PO2) ≤ 80 mmHg. Patients who meet the criteria receive one dose (200 mL) of ABO compatible inactivated convalescent plasma with a confirmed neutralization activity. The recipient are going to undergo detailed clinical evaluation along with the assessment of biochemical parameters, complete blood count and inflammation indicators. The study involves a comprehensive assessment of the serological response of patients with different course of SARS-Cov-2 infection, as well as an analysis of the impact of the level of antibodies in the donor's plasma on the clinical response in patients with COVID-19. In addition, a comprehensive metabolomic analysis of donor and recipient blood was planned to identify prognostic and predictive factors. The endpoints include the safety of convalescents plasma transfusion, as well as the improvement of clinical symptoms and laboratory parameters.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Convalescent Plasma Treatment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

The study is going to recruit 300 convalescent plasma donors and 200 recipients

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hospitalized patients with SARS CoV-2 infection

Hospitalized patients with SARS CoV-2 infection will receive an anti SARS-CoV-2 convalescent plasma

Group Type EXPERIMENTAL

COVID-19 convalescent plasma treatment

Intervention Type BIOLOGICAL

The donor's blood will be collected after four weeks post-onset of illness. 600 ml ABO-compatible plasma sample will be harvested during apheresis from each donor and each sample will be divided and stored as 200 mL aliquots.

Patients who meet the criteria receive one dose (200 mL) of ABO compatible inactivated convalescent plasma with a confirmed neutralization activity.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

COVID-19 convalescent plasma treatment

The donor's blood will be collected after four weeks post-onset of illness. 600 ml ABO-compatible plasma sample will be harvested during apheresis from each donor and each sample will be divided and stored as 200 mL aliquots.

Patients who meet the criteria receive one dose (200 mL) of ABO compatible inactivated convalescent plasma with a confirmed neutralization activity.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Donors:

1. Age \>18 and \<65 years
2. Confirmed previous SARS CoV-2 infection
3. Signed informed consent to participate in this clinical trial, to donate plasma and to store the specimen for future testing.
4. At least 28 days from the end of isolation or resolution of symptoms of infection
5. Male donors, or female donors who have not been pregnant, or female donors who have been pregnant tested negative for HLA antibodies
6. Individuals who meet all regular voluntary donor eligibility requirements

Recipiants:

1. Signed informed consent to participate in this clinical trial.
2. Confirmed previous SARS CoV-2 infection
3. Respiratory distress with tachypnoe ≥30 breaths per minute,
4. Oxygen level less than 94% in resting-state,
5. Partial pressure of oxygen (PO2) ≤ 80 mmHg

Exclusion Criteria

Donors:

1. Age : \<18 or \>65 years
2. Female subjects who are pregnant
3. HIV1,2 hepatitis B,C or syphilis infection
4. Donors ineligible for regular voluntary blood donation

Recipiants:

1. No informed consent to participate in the study
2. Patients with a history of plasma hypersensitivity, including anaphylactic shock in previous transfusions, allergic reactions to citrate or primary IgA deficiency
3. Patients with symptoms of severe multi-organ failure
4. Patients with known allergic reactions to chemical compounds used or generated in the procedure of inactivation of pathogens
5. Patients with active thrombosis

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No